Vivaldi Biosciences is a clinical-stage biotechnology company developing live attenuated influenza vaccines (LAIVs) for greater protection against seasonal influenza and preparedness against emerging pandemic influenza. Live vaccines are considered the gold standard for many other vaccine-preventable vaccines. They safely simulate a natural infection to induce an immune response, provide potent and long-lasting immunity with a low dose, and have an excellent safety record. Vivaldi's LAIV technology platform provides a new influenza vaccine approach with the potential for superior efficacy.
Vivaldi's LAIV technology platform is based on the pioneering work of Vivaldi co-founders Drs. Peter Palese and Adolfo García-Sastre at the Icahn School of Medicine at Mount Sinai (New York, NY) on the influenza virus genome and the biology of influenza nonstructural protein 1 (NS1). NS1 is a multifunctional virulence factor of influenza produced by the virus in infected cells to counter the host immune response. Vivaldi uses proprietary reverse genetics and plasmid rescue technologies to partially or fully delete the gene encoding influenza NS1, generating LAIVs that are safely attenuated, replication-deficient and induce a potent, protective immune response.
Vivaldi's LAIVs are administered as a nasal spray, eliciting an immune response in the nasal passages as a first line of defense at the natural point of entry of circulating viruses, and a robust systemic immune response.
Vivaldi's LAIVs stimulate the body's production of interferon, which acts as a natural adjuvant, activating the cellular immune response and enhancing production of antibodies, including neutralizing antibodies cross-reactive with variant influenza strains. This unique mechanism of action of Vivaldi's LAIVs makes synthetic adjuvants unnecessary and avoids the safety and regulatory hurdles they pose. Manufacturing feasibility of the LAIVs has been demonstrated with egg and Vero cell substrates, addressing established industry practices as well as evolving strategic and commercial needs.
Vivaldi's patent portfolio provides exclusivity and broad freedom to operate using reverse genetics and plasmid rescue technologies for development and manufacturing of LAIVs with modifications of NS1, including exclusivity on issued patents covering LAIVs with intermediate and full deletions of NS1. Vivaldi also has exclusive rights to manufacturing methods in interferon-deficient substrates used in commercialization.
Vivaldi Biosciences Inc. is headquartered in Fort Collins, Colorado, USA. The company's European affiliate, Vivaldi Biosciences AG, is located in Vienna, Austria.